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Background: Understanding the perception of patients on research ethics issues related to biobanking is important
to enrich ethical discourse and help inform policy.
Methods: We examined the views of leukemia patients undergoing treatment in clinics located in the Princess
Margaret Hospital in Toronto, Ontario, Canada. An initial written survey was provided to 100 patients (64.1%
response rate) followed by a follow-up survey (62.5% response rate) covering the topics of informed consent,
withdrawal, anonymity, incidental findings and the return of results, ownership, and trust.
Results: The majority (59.6%) preferred one-time consent, 30.3% desired a tiered consent approach that provides
multiple options, and 10.1% preferred re-consent for future research. When asked different questions on re-consent,
most (58%) reported that re-consent was a waste of time and money, but 51.7% indicated they would feel
respected and involved if asked to re-consent. The majority of patients (62.2%) stated they had a right to withdraw
their consent, but many changed their mind in the follow-up survey explaining that they should not have the right
to withdraw consent. Nearly all of the patients (98%) desired being informed of incidental health findings and
explained that the information was useful. Of these, 67.3% of patients preferred that researchers inform them and
their doctors of the results. The majority of patients (62.2%) stated that the research institution owns the samples
whereas 19.4% stated that the participants owned their samples. Patients had a great deal of trust in doctors,
hospitals and government-funded university researchers, moderate levels of trust for provincial governments and
industry-funded university researchers, and low levels of trust towards industry and insurance companies.
Conclusions: Many cancer patients surveyed preferred a one-time consent although others desired some form of
control. The majority of participants wanted a continuing right to withdraw consent and nearly all wanted to be
informed of incidental findings related to their health. Patients had a great deal of trust in their medical
professionals and publically-funded researchers as opposed to profit-based industries and insurance companies.
Keywords: Biobank, Tissue repository, Cancer patient perspectives, Consent, Withdrawal, Anonymity, Incidental
findings, Return of results, Ownership, TrustBackground
The large-scale collection of biological materials along
with health and demographic information has become an
important research tool in many areas of the biomedical
sciences. Biobanking involves the collection and long-
term storage of biological materials (e.g., blood, DNA,
urine, cells, etc.) and health information. Biobanks are
valuable research platforms that allow for future research* Correspondence: tcaulfld@law.ualberta.ca
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reproduction in any medium, provided the orstudies on stored samples. Investigators can, for example,
analyze data derived from biological samples (i.e., pres-
ence of a gene sequence), and correlate that analysis with
other data (e.g., health information or demographics) to
identify statistical relationships. Biobanking can also
allow the sharing of biological samples with other re-
searchers. Large-scale biorepositories have been viewed
as necessary to improve our understanding of disease
and to develop new diagnostic and treatment modal-
ities. Substantial investments have been made at local,
state, and national levels to create biobanks in juris-
dictions such as the United Kingdom, United States,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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other countries [1-4].
Biobanks have generated a range of ethical and legal
challenges related to privacy, informed consent [5], con-
trol and ownership [6,7], withdrawal of samples and
consent [8], commercialization, return of results and in-
cidental findings [9], and research governance. Indeed,
these issues have generated much policy debate and
have already resulted in several public controversies re-
garding informed consent [10-12], commercialization
[13], and control, and ownership [14-16]. Gaining a
greater understanding of the perspectives of different
stakeholders, including patients who provide biological
samples and health information to biobanks can offer
insight into the nature and drivers of these ethical con-
troversies, inform policy development, and assist in
public engagement.
While there are many studies evaluating public and
patient perspectives on biobanking, only a few capture
the views of Canadians [17-21] and even fewer capture
those of patients. Because patients may be more invested
in research and have different expectations than the gen-
eral public [22], gaining an understanding of the views
of this population will help to provide insight into the
breadth of perspectives relevant to biobanking. In this
study, we performed a survey of leukemia patients re-
ceiving treatment at Princess Margaret Hospital’s
Hematology Oncology Clinic on several issues related to
biobanking, including informed consent, withdrawal,
anonymity, return of results, ownership, privacy, and
trust. Patients were provided with written surveys during
an initial visit and the same survey was provided six
months later in order to determine whether their views
had changed on various ethical and legal issues regard-
ing biorepository research. A six month period provided
sufficient time for patients to receive treatment and
interact with physicians and clinic staff, which may have




As part of a large research study designed to understand
the perspectives of different Canadian stakeholder
groups on biobanking, we recruited 100 patients from
June 22 to October 12, 2011 who received treatment for
leukemia at six different hematology-oncology clinics at
Princess Margaret Hospital in Toronto, Ontario, Canada.
Patients were receiving chemotherapy or other treat-
ment for leukemia and some were in remission. As two
of the authors (MM and JW) are co-directors of the
Princess Margaret Hospital Hematologic Malignancy
Tissue Bank, patients participating in this bank were
invited to participate in our survey as a conveniencesample. All patients were 16 years of age or older, and
the majority lived in the Greater Toronto Area and sur-
rounding municipalities although a few lived in Northern
Ontario. The Greater Toronto Area has a multicultural
and multiethnic population.
Patients were informed by their attending hematologist
that a researcher (JC) might approach them to participate
in the biobank survey. A short consent form explaining
the study was provided along with a verbal explanation.
After consent was obtained, patients were left with the
survey to complete and a copy of the informed con-
sent form. This project received research ethics ap-
proval from the University of Alberta Research Ethics
Board (MS2_Pro00021037) and the University Health
Network Research Ethics Board (11-0380-BE) prior to
patient enrolment.
A total of 100 out of 156 patients participated by
completing the initial survey providing a response rate
of 64.1%. Patients were given ample time to fill out the
survey and most were completed while the patient was
still in the clinic; two patients completed the question-
naire at home and returned it by mail. Seventy eight
patients that participated in the survey had already
consented for their samples to be deposited in the Princess
Margaret Hospital Hematologic Malignancy Tissue Bank
(REB 01-0573-C) at the time the survey was given to
them. At the time of recruitment for the initial survey, pa-
tients were also asked if they would agree to participate in
a follow-up survey six months later. Of the 72 patients
who provided consent to complete a follow-up survey,
only 45 returned a completed follow-up survey giving a
response rate of 62.5%. Of the 100 patients participating
in the initial survey, 60 were male and 40 were female. For
the follow-up survey, 27 males and 18 females participated
thereby maintaining the 60–40 male to female ratio in
both the initial and follow-up surveys.
Survey design and analysis
This survey is part of a larger initiative designed to
understand and compare the opinions of different stake-
holders, including the public [22], on a breath of research
ethics topics related to biobanking. Survey questions
were designed based on (1) a systematic search of the
published academic literature in order to identify the
ethical and legal challenges associated with biobanking
[23], and (2) an analysis of specific surveys on the ethical
and legal issues associated with biobanking. Interviewers
at the University of Alberta’s Population Research La-
boratory pre-tested the survey with 20 Albertans from
May 9-11, 2011 [22].
This study aimed to explore the perspectives of pa-
tients undergoing leukemia treatment where most of the
patients participated in a local biobanking project. The
survey had nine questions containing multiple parts with
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sponses. A copy of the questionnaire is available online
as Additional file 1.
Recruitment of patients and the collection of re-
sponses for the initial and follow-up surveys were done
in Toronto, and subsequent analysis was performed by
researchers affiliated with the University of Alberta. No
patient identifying information was sent to researchers
at the University of Alberta. Comparisons between the
initial and follow-up surveys were done only for those
participants that completed both surveys.
Statistical analysis
Data were tabulated and analyzed using IBM SPSS 19
for Windows. To determine statistical relevance,
Pearson’s Chi-Square (χ2) Tests were performed as we
aimed to determine whether our observed sample of
nominal scale data conformed to an expected distribu-
tion. Statistical significance was determined where the
null-hypothesis (no difference in categories) was rejected
with a p < 0.05. In order to maintain statistical accuracy,
responses where participants chose more than one re-
sponse or failed to respond were not included in the
final count when performing statistical analysis.
As only 45 of the initial 100 patients completed the
follow-up survey we wanted to determine whether there
was a potential bias due to non-response. We compared
responses between those who completed the follow-up sur-
vey with those who did not. Chi-Square tests did not yield
any significant differences in the responses of these two
groups, and therefore, we do not suspect a response bias.
Results
Consent
We first set out to determine patients’ preferences on in-
formed consent for biobanking, asking them to choose
one of three consent models: (a) specific/re-consent,
(b) one-time general consent, and (c) tiered consent.
From our initial set of survey responses, we found that
out of 89 patients that responded, 59.6% preferred one-
time consent while 30.3% preferred a tiered approach,Table 1 Patient preferences of different informed consent ap
Type of consent
Re-consent: The researchers should ask you for your permission to use them
they would like to do a new study
One time consent: The researchers should only ask for your permission to u
thus allowing researchers to use them for as many studies as they would like
Tiered consent: The researchers should provide you with options regarding
studies your stored samples and health information could and could not be
Due to rounding, totals may not equal 100%.and 10.1% preferred to re-consent for every future re-
search project (χ2 = 32.989, df = 2, p < 0.001) (Table 1). Of
the 45 participants that completed both initial and
follow-up surveys, a significant number of responses
changed (n = 20), such that slightly more participants
preferred one-time consent and fewer preferred tiered
consent (χ2 = 47.356, df = 3, p < 0.001) (Table 1).
To further understand patient views on informed con-
sent, we asked participants about their views specific to
re-consenting. Approximately 58% of patients agreed or
strongly agreed that it was a waste of time and money
while 36.6% disagreed or strongly disagreed (χ2 = 22.108,
df = 4, p < 0.001) (Figure 1). Patients had a range of opin-
ions when asked whether they would feel bothered by
re-consenting with differences not being statistically sig-
nificant (χ2 = 5.976, df = 4, p = 0.201). When patients
were asked if they would have more control if asked to
re-consent, about 21.4% disagreed, 30% agreed, and
34.5% were indifferent (Figure 1). Only 7.1% either
strongly agreed or strongly disagreed indicating that only
a few patients had strong views on the topic of control
(χ2 = 26.833, df = 4, p < 0.001). Approximately 40% of
patients reported that they agreed or strongly agreed
on having greater trust in a study if they were
allowed to re-consent, 33.7% were indifferent, while
26.7% disagreed or strongly disagreed (χ2 = 18.651, df = 4,
p = 0.001). Lastly, when we asked patients if they would feel
respected and involved if they were asked to re-
consent, a significant 51.7% agreed or strongly agreed while
18.4% disagreed or strongly disagreed (χ2 = 27.540, df = 4,
p < 0.001) (Figure 1). Follow-up survey responses showed
that more patients had less trust in the study (χ2 = 44.260,
df = 25, p = 0.01) and fewer felt respected and involved
(χ2 = 41.127, df = 25, p = 0.022) than what was reported
by participants in the initial survey (data not shown).
Withdrawal
On the topic of withdrawing consent, we found that
62.6% of patients wanted to have the right to withdraw
their sample and health information from a biobank
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Figure 1 Patient perspectives on re-consenting for each new study. Likert scale responses of leukemia patients’ perceptions on re-consent
was quantified. Question: How would you feel if you had to give permission to use your stored biological sample and health information before
each new study? (a) I would feel it was a waste of time and money. (b) I would feel bothered. (c) I would feel I have control. (d) I would feel
more trust in the study. (e) I would feel respected and involved. * indicates the questions to which patient responses were statistically significant.
Due to rounding, totals may not equal 100%.
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their response on withdrawal in the follow-up survey (data
not shown). This resulted in a significant proportion of
patients moving from wanting to have a right to withdraw
to deciding that they should not have a right to withdraw
consent for future medical research (χ2 = 12.259, df = 4,
p = 0.016) (Table 2).
Anonymity
In order to understand cancer patient perspectives on
anonymity, we asked patients whether it was more im-
portant to have a sample anonymized (described as no
way to trace back to donor) or de-identified (described
as researchers do not readily know who the sample be-
longs to, but there is a way to trace it back to the partici-
pant). The results were split: 54.6% of participants
desired samples to be anonymized while 45.4% desired
de-identification of samples; this difference was not sta-
tistically significant (χ2 = 0.835, df = 1, p = 0.361, n = 97).
The follow-up survey showed an increase in the number
of participants desiring samples to be anonymized in-
stead of de-identified, but these changes were not sta-
tistically significant (χ2 = 3.85, df = 2, p = 0.146).Table 2 Patient perspectives on the right to withdraw inform
Do you think you should have
the right to withdraw:
Initial survey responses
(n = 99) %
Yes 62 62.6
No 37 37.4
Due to rounding, totals may not equal 100%.Return of results
Patients were presented with a scenario in which re-
searchers discovered incidental findings related to their
health, but unrelated to the initial study. They were
asked how researchers should handle this situation: do
nothing, inform them, inform their doctor, or inform
both them and their doctor. Of the 98 participants that
provided responses, only 2% indicated that nothing
should be done and 8.2% preferred to know themselves
(Table 3). Many patients (22.4%) preferred instead that
researchers should notify their physician while most of
the patients (67.3%) preferred that researchers should
inform both them and their doctor (χ2 = 102.327, df = 3,
p < 0.001).
Public health surveillance
We asked participants how they would feel if a policy
was put in place that allowed a public health worker to
analyze their health information and mail information to
them related to potential chronic health risks (e.g., an in-
creased risk of diabetes). We found that the majority
(82.9%) agreed or strongly agreed that the information
would be useful (χ2 = 79.298, df = 4, p < 0.001) while onlyed consent
Follow-up survey responses
Initial (n = 44) % Follow-up (n = 44) %
27 61.4 23 52.3
17 38.6 21 47.7
Table 3 Patient preferences on the return of incidental
findings
What do you think researchers
should do upon discovering
health information?
Initial survey responses
(n = 98) %
Nothing 2 2.0
Tell me 8 8.2
Tell my doctor 22 22.4
Tell both myself and my doctor 66 67.3
Due to rounding, totals may not equal 100%.
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time and a poor use of resources (χ2 = 21.880, df = 4,
p < 0.001) (Figure 2). More participants (50.6%) dis-
agreed or strongly disagreed that their privacy would
be invaded (χ2 = 16.578, df = 4, p = 0.002) (Figure 2). A
significant number of responses changed in the follow-
up survey for two areas. Half of the 44 participants who
completed the follow-up survey changed their mind
resulting in about a 10% decrease of participants who
agreed or strongly agreed that the information would be
useful (χ2 = 51.075, df = 25, p = 0.002). Additionally, in
the follow-up survey, the majority of participants
changed their minds resulting in 10% greater response of
disagreeing or strongly disagreeing that returning health
results was a waste of time and a poor use of resources
(χ2 = 61.140, df = 25, p < 0.001).
Ownership and decision-making
To assess perspectives on ownership, we asked partici-
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Figure 2 Patient perspectives on public health surveillance. Likert scal
where a public healthcare worker identifies and notifies them about pot
system in place that allowed this public healthcare worker to mail this i
status? (a) I would consider the information useful. (b) I would feel it wa
care dollars. (c) I would feel my privacy was invaded. (d) I would feel inparticipant, the researcher conducting the research, the
institution where the research is being conducted, or the
funder(s) of the research. Of the 98 responses received
in the initial survey, the majority of participants (62.2%)
stated that the research institution owned the samples.
But a significant minority reported that research partici-
pants (19.4%) or the researcher (16.3%) owned the sam-
ples. Only 2% explained that the funder owned the
samples (χ2 = 79.224, df = 3, p < 0.001).
On a similar line of questioning, we asked patients if
they had a continuing right to decide what is done with
their samples. Of the 95 responses collected in the initial
survey, 55.8% indicated they should have the right to de-
cide what is done with their samples (χ2 = 1.274, df = 15,
p < 0.259).
Trust
The final question of the survey asked patients about
their levels of trust in different actors and their organi-
zations in regards to the care and use of their confiden-
tial health information. Patients were able to indicate
whether they trusted different individuals or organiza-
tions “A great deal,” “Somewhat,” or “Not at all,” or
they were able to respond as “Don’t know.” Patients
had a great deal of trust in doctors (71.3%) (χ2 = 73.196,
df = 2, p < 0.001), hospitals (63.4%) (χ2 = 55.473, df = 2,
p < 0.001), university researchers funded by government
(40.4%) (χ2 = 37.640, df = 2, p < 0.001), and disease based
foundations (31.2%) (χ2 = 43.103, df = 2, p < 0.001)
(Figure 3). Patients somewhat trusted the government
in their province (56.8%) (χ2 = 37.640, df = 2, p < 0.001),
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Figure 3 Patient perspectives on trust in actors and institutions involved in biobanking. Likert scale response of leukemia patients’
perceptions on their level of trust for different individuals and organizations with the care and use of confidential health information.
Question: How much do you trust the following individuals, organizations or groups with the care and use of your confidential health
information? (a) For-profit industry, for example, a drug company. (b) Insurance industry. (c) Government in your province. (d) Data collection
organizations (Stats Canada/Canadian Institute for Health Information). (e) University research funded by industry. (f) Disease based foundation
(e.g., Kidney Foundation, Heart & Stroke). (g) University researchers funded by government. (h) Hospitals. (i) Doctors. Due to rounding, totals
may not equal 100%.
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52.966, df = 2, p < 0.001), and industry-funded univer-
sity research (59.8%) (χ2 = 32.719, df = 2, p < 0.001)
(Figure 3). Most patients had quite low levels of trust
towards for-profit industry (61.7%) (χ2 = 52.621, df = 2,
p < 0.001) and the insurance industry (56.7%) (χ2 =
44.923, df = 2, p < 0.001). Of those patients who com-
pleted the follow-up survey, 16 participant responses
changed such that there was even less trust towards
for-profit industry (χ2 = 27.856, df = 12, p = 0.006), and
15 participants changed responses showing slightly less
trust towards hospitals (χ2 = 7.979, df = 3, p = 0.046)
(data not shown).
Discussion
Much public perception research on the ethical and legal
aspects of research involving biobanks has been
performed with patient populations, including adults
and children, and healthy volunteers (e.g., general public,
US veterans, and racial groups) in many jurisdictions.
Yet little research has been conducted to specifically as-
sess the perceptions of Canadian cancer patients. Sur-
veying Canadian cancer patient perceptions provides an
opportunity to compare these perceptions to those of
different populations surveyed in other research studies.
This work helps to provide a picture of the breadth of
opinions relevant to the ethical and legal controversies
associated with biobanking.
Consent
The topic of informed consent as it relates to biobanking
has dominated public perception studies. A recent re-
view shows that 51% of the 87 different empirical studieson biobanking discuss stakeholder perceptions on con-
sent [23]. In our study, we limited our question to three
consent types, despite the multitude of possible consent
models for biobanking, so as to maintain simplicity in
our questionnaire and because many of the ethical and
legal issues for other variations of consent are similar
[24]. Our results clearly showed that of the three op-
tions provided (re-consent, one-time consent, and
tiered consent), the majority of patients (59.6%) pre-
ferred a one-time consent. However, many preferred a
form of consent that was more specific and ongoing in
nature (e.g., some preferred to re-consent and nearly a
third chose tiered consent). Our results corroborate
findings from some studies done in other jurisdictions.
One study analyzing consent preferences from breast
cancer survivors in the Netherlands showed that 61% in-
dicated that they would like to choose the type of future
research, 56% preferred a one-time general consent
model, and 45% indicated that they would rather give
permission for the current research, but not for other fu-
ture research [25]. Another study examined the views on
consent of African American and White American can-
cer patient groups who attended two healthcare facilities
in Atlanta, Georgia. The researchers found that although
the vast majority of patients from both cohorts were will-
ing to participate (95%), 57% desired that researchers
choose the type of future research using their samples
while 10% wanted to choose using a checklist of options,
and 33% explained either option would be fine [26]. It is
unknown why there are differences between different
populations of cancer patients, but many factors could
influence the difference in opinions including the ways in
which the questions were posed in the surveys.
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may or may not be patients) are in some respects
comparable, but interesting differences are also
present. In contrast to our study, a US nationwide
study that offered participants different choices showed
that 48% preferred blanket consent (consent for any
future research), 42% preferred being asked at the ini-
tiation of each study, and 10% preferred tiered consent
[27]. In addition, a study conducted by our group sur-
veying 1201 Albertans demonstrated that 51.8% pre-
ferred one-time consent, 30.2% chose tiered consent,
and 18.0% preferred re-consent [22]. The slightly
higher preference for a one-time consent by patients
as compared to those in the general public may be
due to their personal interest in the research and the
high degree of trust in their medical team. In total,
these results are similar to findings from our study
and indicate that while the majority of participants are
comfortable with a one-time consent, many prefer
tiered consent or re-consent approaches indicating a
desire for control.
We asked patients additional questions on re-consent
and compared our results to a survey of 1201 Albertans
[22], and a nationwide study of approximately 8735
Americans [27] (Table 4). Approximately 58% of pa-
tients and Albertans reported that re-consent was a
waste of time and money compared to only 27% of
Americans. Interestingly, 33.7% of patients and 26% of
Americans thought it would be bothersome to re-
consent in contrast to 51.9% of Albertans who felt
this way. On other points, it seemed overall that can-
cer patient opinions from our survey on control, trust,
or feeling respected and involved differed from the
US general public and aligned more with the views of
Albertans (Table 4). One possible explanation is that
perhaps cancer patients, a group that has frequent
interaction with the healthcare system, have a higher
degree of trust in their physicians and researchers
than the general public. Their situation may also
mean that they view the relevant research as import-
ant and, as a result, feel less need to provide specific
and ongoing consent.Table 4 A comparison of opinions on re-consenting for future
Patient survey (%)





It was a waste of time & money 58.1 36.6
Bothered 33.7 45.8
I have control 36.9 28.5
More trust in the study 39.5 26.7
Respected and involved 51.7 18.4
Due to rounding, totals may not equal 100%.Withdrawal
Very little public perception research covers the topic of
withdrawing consent in the context of biobanking [23]
and in many cases questions surrounding withdrawal are
intimately tied to issues of privacy, consent, and trust.
Most of the patients in our study (62.6%) wanted to have
the right to withdraw consent at any time. Our results
found less support for unlimited withdrawal as com-
pared to Albertans, where 71.2% indicated that partici-
pants should have a right to withdraw [22]. However,
our results were similar to a Swedish study where 62%
of participants reported feeling positive about the right
to withdraw [28]. Yet there are studies that have found
very different results. For example, an evaluation of 600
adult Egyptian patients found that only 28.8% believed
in the right to withdraw their blood samples [29]. There
is also evidence to suggest that some participants do not
perceive a reason to withdraw, but feel it is an option
that should be maintained in case others had concerns
about the study [30]. Reasons for withdrawal could in-
clude a breach of security or scandal, negative news
media about the research, changes to a participant’s
health status, burdensome requests from researchers,
and negative responses from peers [31]. Most interesting
was that compared to the initial survey results, more pa-
tients indicated that they should not have the right to
withdraw in the follow-up survey. We speculate that this
observation may be partially explained by the high de-
gree of trust patients place in university-funded re-
searchers and medical staff, and that they believe that
biobanking research could advance medical treatments
for leukemia.
The right to withdraw from research is supported by
virtually all research ethics policies, but there are is-
sues with the practicality of withdrawing consent as it
relates to biobanking. Some are concerned that the
right to withdraw consent for biobanking may be erod-
ing because it could cause sample bias in a given
population [32-34]. Yet withdrawing consent is a fun-
damental research ethics norm [35]. Overall, results
from our study showed that patients reported they
should have the right to withdraw consent at any time.biobanking research









27 73 58.5 30.8
26 74 51.9 39.1
75 25 51.0 32.5
75 25 48.1 34.8
81 19 56.7 26.5
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samples from cancer patients is determining who has
the authority to withdraw samples when there is no
legal will or declaration of a proxy. This is especially
important in the case of collecting and storing samples
from cancer patients because patients could die soon
after donation. Additional empirical research examining
the complexities of the right to withdraw and the per-
ceptions of different stakeholders is needed.
Anonymity
Patient preferences of whether samples are either
deidentified or fully anonymized and cannot be traced back
to the donor were roughly 50–50. Yet having samples fully
anonymized becomes problematic when collecting and
storing samples involving cancer patients because the diag-
nosis of samples is linked to the tailoring of treatment regi-
mens for individual patients. It is unclear from our
questionnaire whether patients understood this caveat
when responding to the survey question.
Return of results
In general, research tells us that the general public and
patients have a strong desire to receive individual results
either for them or their descendants [23]. Our results
confirm this trend. Indeed, about 98% of those surveyed
wanted this information to be disclosed to themselves,
their physicians, or both. This is, in fact, one of the few
areas of almost universal agreement.
These results are similar to the perceptions of
Albertans where 90% of participants wanted to be in-
formed of research results in some way [22]. In general,
many studies confirm that the public and patients have a
strong preference to know research results [29,36-38].
However upon further examination of the types of re-
search results participants desire, the numbers differ.
Several studies indicate that many participants want to
receive results in situations where treatment options are
available and have a lower desire to know results for ei-
ther untreatable conditions or where the significance of
the finding is not well understood [39-41]. Our results
clearly show that cancer patients have a high desire to
know the results of research. Yet we reason that if pa-
tients were provided details on the different types of re-
sults that might be returned, their views are likely to be
nuanced as we have seen in other studies.
Ownership and decision making
In the few surveys that capture perceptions on owner-
ship, about 23-53% of participants report that the partici-
pant themselves are the owners of the samples
[25,41,42]. Surprisingly, our survey results showed that
only 19.4% of patients believed they were the owners and
the majority (62.2%) believed that research institutionsowned the samples. The survey of Albertans also showed
a relatively high number of participants (44.3%) believed
that the research institution owned samples, although a
significant minority (25.7%) of respondents believed they
owned the samples [22]. We speculate that the high
number of patients believing that the research institution
owns the samples could be because they perceive
government-funded researchers to be trustworthy and,
therefore, feel comfortable with the research institution
having an ownership-like interest. In addition, as we did
not define the term “research institution,” patients may
conflate research institution with the hospital where they
were treated (which, admittedly, is often the case). This
explanation is supported by another study that observed
that many patients responded that the hospital owned
the samples [42]. Yet despite many patients believing that
research institutions own samples, the majority of pa-
tients (55.8%) indicated that they have the right to decide
what is done with their samples. These findings are
reinforced from a study showing that many participants
prefer multiple data sharing options and want some con-
trol on decision-making [43]. More research is needed to
better understand participant conceptions of ownership,
the right to decide, and the factors that influence desires
for control over their samples and health information.
Trust
Patients reported higher levels of trust in doctors, hos-
pitals, and government-funded university researchers,
moderate levels of trust in their provincial government,
and low levels of trust in for-profit industry and insur-
ance companies. Near identical results were also seen
when surveying Albertans [22] and similar findings
were seen in other public perception research [44,45].
Other than trusting actors in various organizations,
there is some data suggesting that participants show
less trust of biorepository research that has the poten-
tial to cause stigmatization or discrimination, or goes
against deeply held cultural or religious beliefs, e.g.,
lineage determination, behavioral disorders, and in-
breeding [5,10,20,36,44,45]. Although our survey ques-
tions did not discuss the different areas in which
research samples may be used, in general, cancer pa-
tients have similar high levels of trust in the organiza-
tions as seen in other studies [22].
Limitations
The survey has several important limitations that merit
discussion. It considers the opinions of leukemia patients
from a specific geographical location, and opinions of
cancer patients from other areas or other types of pa-
tients (i.e., surgical) may vary. To maintain anonymity,
our survey did not gather information related to age,
education, ethnicity, or religious background or belief
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responses. One limitation specific to our survey was
that some participants did not complete questions
containing multiple parts (e.g., A through E) where
each part required a single Likert scale response. We
suspect that this may be due to misinterpreting the in-
structions which asked for a single response to each
part, and this may bias responses as these were ex-
cluded from the analysis. As our survey was meant to
capture broad patient perspectives and compare them
with those of other Canadian stakeholders, we did not
pose questions that attempted to determine the rea-
sons behind participant responses. Future qualitative
research with cancer patients would complement our
survey and permit a richer understanding of reasons
behind differing viewpoints.
Conclusions
Our survey results of Canadian cancer patients’ percep-
tions on the ethical and legal issues of biobanking
showed several interesting differences and similarities
with the results of other surveys. Results on consent
showed that many patients desire some form of control.
As with most other studies, there seems to be general
agreement that returning results of research and
allowing participants to withdraw consent are desirable
practices. It is interesting to note that as compared to
the results of other surveys, more patients in our study
felt that they should not have the right to withdraw con-
sent. Although a statistically relevant association was not
found, we speculate that because this patient population
has a high degree of trust in their doctors, the hospital,
and university-based researchers, they may not feel as
strongly about a need for a right to withdraw. In
addition, their belief in the importance of biobanking re-
search for leukemia may also influence their views. Simi-
larly, the high numbers of patients believing that the
research institution owns their samples could also be
explained, in part, by the elevated levels of trust they
have for their clinical staff and researchers. Our study is
one of a few that examines Canadian patient perceptions
on biobanking and provides an important contribution
to the broader understanding and public discourse sur-
rounding biobanking, and thus has relevance for the de-
velopment of research policy on biobanking.
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